Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Marvel Biosciences has signed a letter of intent with Novatech to manage Phase 1 trials of its drug candidate MB-204 in Australia. This agreement covers both single ascending dose (SAD) and multiple ascending dose (MAD) studies, marking a progression from preclinical development toward first-in-human testing.
Marvel Biosciences signed a letter of intent with Novatech to run a Phase 1 clinical program for autism candidate MB-204. Trial planned in Australia, targeting first-in-human safety, tolerability, and pharmacokinetics; single ascending dose study expected to start in Q4 2026.